Dr. Carlos Coronell Coronell

Clinical Development Program on brigatinib Phase 3 study in patients with lung cancer (NSCLC ALK+) Maintain bilateral communication and solid professional relationships between site PIs, investigator teams, KOLs and Pharmaceutical’s medical department to support the medical/scientific information and research needs. Develop and conduct training sessions on scientific/medical information at specific training events and site initiation visits.

Provide strategic and tactical medico-scientific advice and expertise supporting the Dysport™ European Business Unit. Working with adult muscle spasticity, cervical dystonia and cerebral palsy as indications of botulinum toxin A. Suggest, direct and manage new medical, scientific, and clinical trial and communication initiatives that will support and help deliver medium and long-term profitable business growth, within the strategic framework of the Ipsen Group.

•Communicate complex scientific data to healthcare customers, key opinion leaders within the therapeutic area in South Europe (Spain, Portugal, Italy, Turkey, etc...) and East Europe (Romania, Poland, Czech Republic, Russia, etc...). •Build relationships with KOLs. •Provide expert opinion in data analysis and development of scientific publications, including economic outcomes data. •Responsible for partnering with investigators to execute investigator initiated studies.

•Communicate complex scientific data to healthcare customers, key opinion leaders within the therapeutic area. •Build relationships with and present clinical data to key therapeutic area opinion leaders and customers. •Provide expert opinion in clinical data analysis and development of original scientific publications within the therapeutic area, including economic outcomes data. •Responsible for partnering with investigators in the therapeutic area to develop and execute investigator initiated studies.

•Generate awareness, education and interest about the clinical benefits and need for the IRIDICA System™ in the Iberia area •Communicate complex scientific data to healthcare customers and key opinion leaders •Build relationships to key opinion leaders and customers •Provide expert opinion in clinical data analysis and development of original scientific publications, including economic outcomes data •Responsible to develop and execute investigator initiated studies

Scientific support to belimumab (Benlysta™) for the treatment of adult patients with active systemic lupus erythematosus (SLE).

Scientific support to pediatric vaccines, such as Infanrix Hexa™, Boostrix™, Ditanrix™, Varilrix™, Priorix™, Priorix Tetra™, Synflorix™, and Rotarix™, and others vaccines.

Scientific support to belimumab (Benlysta®) for the treatment of adult patients with active systemic lupus erythematosus (SLE), and other antibiotic drugs.

Cardiovascular and Central Nervous System (CNS) therapeutical areas. Anticoagulant area for dabigatran (Pradaxa®) for stroke prevention in patients with atrial fibrillation (SPAF), prevention and treatment of venous thromboembolism (VTE). Antihypertensive area for telmisartan (Micardis®). CNS area for pramipexol (Mirapexin®) for Parkinson's disease.

Medical Advisor, Anticoagulation area, for prevention of venous thromboembolism after total knee and hip replacement, and stroke prevention in patients with atrial fibrillation Asesor Medico Área de Anticoagulación Tromboprofilaxis después de reemplazo electivo de Cadera y Rodilla. Prevención de Ictus en Pacientes con Fibrilación Auricular (SPAF).

Medical Adviser Central Nervous System (CNS), workin on Parkinson' disease, Restless Legs Syndrome, Depression, and women's Hypoactive Sexual Desire Disorder. Asesor Médico, Área de Sistema Nervioso Central (Enfermedad de Parkinson, Síndrome de Piernas Inquietas, Trastornos Depresivos, Trastornos del Deseo Sexual Hipoactivo en la Mujer)

Departamento: Sanidad - Salud, Estudiar la disfunción muscular en los pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)

Departamento: Sanidad - Salud, Estudio de Disfunción muscular en pacientes con EPOC.

Head of Immunology and Genetics Laboratory, Hospital Metropolitano, Barranquilla, Colombia. Medical Faculty Lecturer, Immunology, Medicine Faculty, Universidad Metropolitana, Barranquilla, Colombia. Director, Laboratorio de Inmunología y Genética, Universidad Metropolitana, Barranquilla, Colombia. Responsable de la Cátedra de Inmunología, Facultad de Medicina, Universidad Metropolitana, Barranquilla, Colombia.

Guest Reseacher Division of Immunogenetic Dana-Farber Cancer Institute Department of Immunology, Cancer and Aids, Harvard Medical School Boston, MA USA.

Head of Immunology and Genetics Laboratory, Hospital Metropolitano, Barranquilla, Colombia. Medical Faculty Lecturer, Immunology, Medicine Faculty, Universidad Metropolitana, Barranquilla, Colombia. Director, Laboratorio de Inmunología y Genética, Universidad Metropolitana, Barranquilla, Colombia. Responsable de la Cátedra de Inmunología, Facultad de Medicina, Universidad Metropolitana, Barranquilla, Colombia,

Asocciated Researcher, Instituto de Inmunología, area of Malaria (synthetic vaccine), Leprosy and Tuberculosis (immunodiagnosis), Hospital San Juan de Dios, Bogotá, Colombia. Investigador Asociado, Instituto de Inmunología, área de Malaria (vacuna sintética), lepra y tuburculosis (inmunodiagnóstico), Hospital San Juan de Dios, Bogotá, Colombia.

Pharmaco-economics

Muscle Physilogy in Patients with COPD